Search

SAŽETAK Uvod: Hipovitaminoza vitamina D je danas široko zastupljena u svetu, u svim starosnim grupama sa većom prevalencom kod žena, posebno kod žena sa osteopenijom i primarnom osteoporozom. Cilj ove studije jeste razvijanje populacionog farmakokinetičkog (PFK) modela klirensa 25-hidroksi vitamina D, identifikacija i kvantifikacija faktora koji ga određuju kod žena starijih od 35 godina, kao i ispitivanje korelacije serumskih 25-hidroksi vitamina D sa vrednostima mineralne gustine kostiju, godinama starosti, kvalitetom života, stepenom depresivnosti i prisustvom straha kod ispitanica. Ispitanici i Metode istraživanja: Studija je obuhvatila 224 žene starije od 35 godina, koje su dolazile na osteodenzitometrijiski pregled u Kliniči centar Kragujevac. Ispitavana populacija podeljena je u tri podgrupe: žene u premenopauzi (od 35. godine do menopauze), žene u peri i/ili postmenopauzi (od menopauze do 65. godine života) i starije žene (od 65. do 75. godine života). U PFK analizi korišćen je softverski program NONMEM (Non linear mixed effect model) i ADVAN 1 subrutina. Brojni demografski, klinički, biohemijski, hormonski i medikamentozni podaci su isptivani kao faktori varijabilnosti klirensa 25-hidroksi vitamina D u sve tri subpopulacije žena. Procena depresije, staha i kvaliteta života je vršena upotrebom validiranih i kulturološki adaptiranih upitnika. Rezultati: Dobijene se srednje, populacione vrednosti klirensa 25-hidroksi vitamina D, identifiokavani su i kvantifikovani faktori koji ga određuju, kao i vrednosti inter- i intraindividulane varijabilnosti u ispitivanim subpopulacijama. Za validaciju dobijenih PFK modela korišćena je eksterna validacija. Pokazano je postojanje korelacije između serumskih koncentracija 25-hidroksi vitamina D sa kvalitetom života kod žena sa redovnim menstrualnim ciklusom; mineralnom gustinom kostiju i vrednostima T skora dobijenih DXA metodom i kvalitetom života kod žena u postmenopauzi. Zaključak: Dobijene farmakokinetiče jednačine mogu, Introduction: Hypovitaminosis of vitamin D is widely spread over the world, throughout every age group, but, dominantly present in female population with osteopenia and primary osteoporosis. The aim of this study was to develop a population pharmacokinetics (PFK) model of 25-hydroxy vitamin D clearance, identification and quantification of factors defining it in female's population older than 35 years, as well as to research the correlations between serum concentration of 25-hydroxy vitamin D and values of bone density, age, life quality, depression level and presence of fear among the study subjects. Patients and Methods: The study population consisted of 224 women older than 35 years, which were taking osteodensitometry tests in Clinical center in Kragujevac. Test population was divided into 3 subgroups: women in premenopause (from 35 years to menopause) and women in peri- and/or in postmenopause (between menopause and 65 years of age) and elderly women (from 65 to 75 years of age). For PFK analysis a NONMEM (Non linear mixed effect model) softwear was used as well as ADVAN 1 subroutine. Numerous demographic, clinical, biochemical, hormonal and medicamental data were investigated as factors of clearance variability of 25-hydroxy vitamin D for all three female subpopulations. Results: Middle values for population clearance of 25-hydroxy vitamin D were acquired, its defining factors were identified and quantified, as well as inter- and intraindividual variables for study population. For validation of acquired PFK models external validation was applied. Correlation between serum concentration of 25-hydroxy vitamin D and life quality for females with regular period, mineral bone density and values for T score from DXA method and life quality for females in postmenopause, was confirmed. Conclusion: Defined pharmacokinetic equations can be used for making recommendation, corrections and individualization of vitamin D doses, through supplementation, for women in